A second group of “driver” mutations involves the small GTPase Neuroblastoma rat sarcoma viral oncogene homolog (NRAS) proto-oncogene, representing 15–20% of all the BRAF-WT melanoma patients. The gene discussed is NRAS; the disease is melanoma.